JP2016516091A - 血管新生の誘導および調節のための組成物および方法、ならびに血管新生調節因子を同定する方法およびアッセイ - Google Patents

血管新生の誘導および調節のための組成物および方法、ならびに血管新生調節因子を同定する方法およびアッセイ Download PDF

Info

Publication number
JP2016516091A
JP2016516091A JP2016506585A JP2016506585A JP2016516091A JP 2016516091 A JP2016516091 A JP 2016516091A JP 2016506585 A JP2016506585 A JP 2016506585A JP 2016506585 A JP2016506585 A JP 2016506585A JP 2016516091 A JP2016516091 A JP 2016516091A
Authority
JP
Japan
Prior art keywords
extract
angiogenesis
human
placental
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016506585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516091A5 (cg-RX-API-DMAC10.html
Inventor
ピーター エス． マクフェトリッジ、
ピーター エス． マクフェトリッジ、
マーク シー． ムーア、
マーク シー． ムーア、
Original Assignee
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド, ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド filed Critical ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Publication of JP2016516091A publication Critical patent/JP2016516091A/ja
Publication of JP2016516091A5 publication Critical patent/JP2016516091A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3808—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1347—Smooth muscle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/04—Screening or testing on artificial tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
    • C12N2533/92—Amnion; Decellularised dermis or mucosa

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
JP2016506585A 2013-04-02 2014-04-02 血管新生の誘導および調節のための組成物および方法、ならびに血管新生調節因子を同定する方法およびアッセイ Pending JP2016516091A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361807401P 2013-04-02 2013-04-02
US61/807,401 2013-04-02
PCT/US2014/032696 WO2014165602A1 (en) 2013-04-02 2014-04-02 Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators

Publications (2)

Publication Number Publication Date
JP2016516091A true JP2016516091A (ja) 2016-06-02
JP2016516091A5 JP2016516091A5 (cg-RX-API-DMAC10.html) 2017-05-18

Family

ID=51621067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016506585A Pending JP2016516091A (ja) 2013-04-02 2014-04-02 血管新生の誘導および調節のための組成物および方法、ならびに血管新生調節因子を同定する方法およびアッセイ

Country Status (8)

Country Link
US (2) US9821013B2 (cg-RX-API-DMAC10.html)
EP (1) EP2981273B1 (cg-RX-API-DMAC10.html)
JP (1) JP2016516091A (cg-RX-API-DMAC10.html)
KR (1) KR20150139569A (cg-RX-API-DMAC10.html)
AU (1) AU2014248198B2 (cg-RX-API-DMAC10.html)
CA (1) CA2908562A1 (cg-RX-API-DMAC10.html)
HK (1) HK1221402A1 (cg-RX-API-DMAC10.html)
WO (1) WO2014165602A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5505760B2 (ja) 2005-09-27 2014-05-28 ティッシュテク・インコーポレーテッド 羊膜調製物及び精製組成物及びその使用方法
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
US9682044B2 (en) 2011-06-10 2017-06-20 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
HK1221402A1 (zh) 2013-04-02 2017-06-02 University Of Florida Research Foundation, Inc. 用於诱导并调节血管生成的组合物和方法以及用於鉴别血管生成调节剂的方法和实验
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
US10342831B2 (en) 2015-05-20 2019-07-09 Tissuetech, Inc. Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
US12551509B2 (en) 2015-11-18 2026-02-17 Lucina Patent Holdco, Llc Acellular regenerative products and methods of their manufacture
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
WO2020036245A1 (ko) * 2018-08-17 2020-02-20 고려대학교 산학협력단 인간 신경줄기세포의 기능강화 및 생산을 위한 태반유래 세포 조건화 배지 및 이의 용도
US20210369630A1 (en) * 2018-10-17 2021-12-02 University Of Florida Research Foundation Magnetically responsive composite microparticles for triggered delivery of biologically active agents
WO2020201488A1 (en) 2019-04-04 2020-10-08 Hackethal Johannes A novel human-material-based platform technology for tissue engineering
EP4398888A1 (en) * 2021-09-07 2024-07-17 Plakous Therapeutics, Inc. Acellular placental therapies

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62129222A (ja) * 1985-08-30 1987-06-11 アメリカ合衆国 細胞培養組成物およびその用途
JPS63152322A (ja) * 1986-09-30 1988-06-24 Ichimaru Pharcos Co Ltd プラセンタ−組織由来フイブロネクチン含有溶液
JPS63501953A (ja) * 1985-12-17 1988-08-04 サイナ−ゲン，インコ−ポレ−テツド 毛管内皮細胞プロテア−ゼ合成、ｄｎａ合成および遊走を促進することの出来るヒト胎盤血管形成誘導因子
JPH0931100A (ja) * 1995-07-24 1997-02-04 Nippon Ham Kk 変性コラーゲン及びその製造方法
WO2003082305A1 (en) * 2002-04-03 2003-10-09 Naohide Yamashita Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells
JP2004517117A (ja) * 2001-01-05 2004-06-10 バイロメッド・リミテッド 抗血管新生タンパク質をコードする遺伝子またはその部分を含む慢性関節リウマチ治療用医薬組成物
JP2005065661A (ja) * 2003-08-20 2005-03-17 Akihiro Yamaguchi ヒト血管内皮細胞のＶＥＧＦ誘導性活性化及び血管新生におけるＩｄの役割
JP2009510091A (ja) * 2005-09-27 2009-03-12 ティッシュテク・インコーポレーテッド 羊膜調製物及び精製組成物及びその使用方法
JP2010539938A (ja) * 2007-09-24 2010-12-24 ノーティス，インク． 灌流可能な微小血管システムを作製するための方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994559A (en) 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
CA2005600A1 (en) 1988-12-20 1990-06-20 Cal-Henrik Heldin Endothelial cell growth factor
AUPM425294A0 (en) * 1994-03-04 1994-03-31 Australian National University, The In-vitro angiogenesis assay
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
EP1183358A1 (en) 1999-06-07 2002-03-06 Edwards Lifesciences Corporation Targeted angiogenesis
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
CN1658848A (zh) 2002-04-12 2005-08-24 细胞基因公司 血管生成调节剂的鉴定方法,由此发现的化合物和使用该化合物的治疗方法
US8940292B2 (en) * 2003-01-28 2015-01-27 Wake Forest University Health Sciences Enhancement of angiogenesis to grafts using cells engineered to produce growth factors
US8192348B2 (en) * 2003-07-01 2012-06-05 Regents Of The University Of Minnesota Engineered blood vessels
US7775965B2 (en) 2004-03-09 2010-08-17 The Board Of Regents Of The University Of Oklahoma Decellularized grafts from umbilical cord vessels and process for preparing and using same
US8187639B2 (en) * 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US20080131522A1 (en) 2006-10-03 2008-06-05 Qing Liu Use of placental biomaterial for ocular surgery
KR20200136051A (ko) 2007-09-26 2020-12-04 안트로제네시스 코포레이션 인간 태반 관류액으로부터의 혈관형성 세포
WO2009100128A1 (en) * 2008-02-04 2009-08-13 Massachusetts Institute Of Technology Particulate delivery vehicles for embryoid bodies
WO2009116951A2 (en) * 2008-03-17 2009-09-24 Agency For Science, Technology And Research Microcarriers for stem cell culture
US8685634B2 (en) * 2009-03-06 2014-04-01 University of Pittsburgh—of the Commonwealth System of Higher Education Neural scaffolds
US9186365B2 (en) 2009-07-31 2015-11-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antiangiogenic small molecules and methods of use
KR101118017B1 (ko) 2009-09-04 2012-02-24 (주)차바이오앤디오스텍 태반 추출물을 제조하는 방법 및 태반 추출물
CN102822521B (zh) * 2010-03-30 2016-01-27 西门子公司 具有间接蒸发的太阳能热发电站和运行这种太阳能热发电站的方法
KR20140071813A (ko) 2012-12-04 2014-06-12 삼성전자주식회사 파이버 상에 형성된 저항성 메모리 소자 및 그 제종 방법
HK1221402A1 (zh) 2013-04-02 2017-06-02 University Of Florida Research Foundation, Inc. 用於诱导并调节血管生成的组合物和方法以及用於鉴别血管生成调节剂的方法和实验

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62129222A (ja) * 1985-08-30 1987-06-11 アメリカ合衆国 細胞培養組成物およびその用途
JPS63501953A (ja) * 1985-12-17 1988-08-04 サイナ−ゲン，インコ−ポレ−テツド 毛管内皮細胞プロテア−ゼ合成、ｄｎａ合成および遊走を促進することの出来るヒト胎盤血管形成誘導因子
JPS63152322A (ja) * 1986-09-30 1988-06-24 Ichimaru Pharcos Co Ltd プラセンタ−組織由来フイブロネクチン含有溶液
JPH0931100A (ja) * 1995-07-24 1997-02-04 Nippon Ham Kk 変性コラーゲン及びその製造方法
JP2004517117A (ja) * 2001-01-05 2004-06-10 バイロメッド・リミテッド 抗血管新生タンパク質をコードする遺伝子またはその部分を含む慢性関節リウマチ治療用医薬組成物
WO2003082305A1 (en) * 2002-04-03 2003-10-09 Naohide Yamashita Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells
JP2005065661A (ja) * 2003-08-20 2005-03-17 Akihiro Yamaguchi ヒト血管内皮細胞のＶＥＧＦ誘導性活性化及び血管新生におけるＩｄの役割
JP2009510091A (ja) * 2005-09-27 2009-03-12 ティッシュテク・インコーポレーテッド 羊膜調製物及び精製組成物及びその使用方法
JP2010539938A (ja) * 2007-09-24 2010-12-24 ノーティス，インク． 灌流可能な微小血管システムを作製するための方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOSCIENCE REPORTS, vol. 5, JPN6017049123, 1985, pages 783 - 790, ISSN: 0004008859 *
日本創傷治癒学会プログラム・抄録集, vol. 42nd, JPN6017049125, 2012, pages 152 - 094, ISSN: 0004008860 *

Also Published As

Publication number Publication date
AU2014248198A1 (en) 2015-10-29
US20140294780A1 (en) 2014-10-02
AU2014248198B2 (en) 2018-11-29
EP2981273A1 (en) 2016-02-10
KR20150139569A (ko) 2015-12-11
CA2908562A1 (en) 2014-10-09
EP2981273A4 (en) 2016-10-26
US9821013B2 (en) 2017-11-21
WO2014165602A1 (en) 2014-10-09
US10300091B2 (en) 2019-05-28
HK1221402A1 (zh) 2017-06-02
US20170209497A1 (en) 2017-07-27
EP2981273B1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
US9821013B2 (en) Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators
JP7854806B2 (ja) 幹細胞／前駆体の固形器官へのパッチ移植
Baldwin et al. Periosteum tissue engineering in an orthotopic in vivo platform
Choi et al. Gelatin-based micro-hydrogel carrying genetically engineered human endothelial cells for neovascularization
JP6821908B2 (ja) 哺乳動物種における誘導組織再生のための組成物および方法
Browne et al. Modulation of inflammation and angiogenesis and changes in ECM GAG-activity via dual delivery of nucleic acids
EP2210622B1 (en) Therapeutic agent for heart disease, which is intended to be used in cell transplantation therapy
KR102339700B1 (ko) 입자상 탈세포화 조직을 포함하는 하이브리드 겔
Papageorgiou et al. Expanded skeletal stem and progenitor cells promote and participate in induced bone regeneration at subcritical BMP-2 dose
Taylor et al. Hypoxic preconditioning of myoblasts implanted in a tissue engineering chamber significantly increases local angiogenesis via upregulation of myoblast vascular endothelial growth factor‐A expression and downregulation of miRNA‐1, miRNA‐206 and angiopoietin‐1
Zhang et al. Transplantation of olfactory ensheathing cells combined with chitosan down-regulates the expression of P2X7 receptor in the spinal cord and inhibits neuropathic pain
Miles et al. In vitro porcine blastocyst development in three‐dimensional alginate hydrogels
KR20220162201A (ko) 소장 유래 줄기세포를 포함하는 소장 오가노이드의 제조 방법 및 이의 용도
Komez et al. A two-compartment bone tumor model to investigate interactions between healthy and tumor cells
Maiborodin et al. Morphological changes in rat uterine tissues and possibility of spontaneous labor as a result of injection of multipotent mesenchymal stromal cells against the background of hydrometra
EP2607478A1 (en) Phenanthroline treated MSC
KR20150072088A (ko) 3차원 세포이식용 패치 및 그의 제조방법
Maiborodin et al. Angiogenesis in rat uterine scar after introduction after autological mesenchymal stem cells of bone marrow origin
Parisi et al. A volume-stable collagen matrix promotes osteogenesis and osteoinduction in cleft lip fibroblasts: A novel approach for alveolar cleft repair
KR101972450B1 (ko) 생체적합성 조직을 제조하는데 사용하기 위한 조성물, 그를 제조하는 방법 및 상기 조성물을 이용한 혈관 형성이 필요한 질병을 치료하는 방법
KR20160147055A (ko) 서방형 혈관신생 조절용 조성물 및 혈관신생 유도 및 조절을 위한 방법
Offiah Novel 3D bench top model for vascular calcification research
Früh Adipose tissue-derived microvascular fragments: A novel prevascularization strategy in skin tissue engineering
Fernandes et al. Phenanthroline treated MSC
Bernier Uniaxially aligned, porous collagen-GAG scaffolds for in vitro modeling of trabecular meshwork

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190402